417P New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study

Viola Cogliati ,R Palumbo,U.F.F De Giorgi,Serena Capici ,Emanuela Rossi ,Francesca Riva ,Marco Mazzotta ,Antonella Ferro ,Massimo Ambroggi ,Monica Giordano ,Patrizia Vici ,Fulvio Borella ,Elisabetta Landucci ,G Moretti ,Ornella Garrone ,Fable Zustovich ,Rossana Berardi ,Luigi Coltelli ,Antonella Turla ,Marina Elena Cazzaniga

doi:10.1016/j.annonc.2023.09.594

Abstract

417P New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study

Full Text